共查询到20条相似文献,搜索用时 15 毫秒
1.
Mary Frances McAleer Patrick Melchior Jeannette Parkes Luke Pater Christian Rübe Daniel Saunders Arnold C. Paulino Geert O. Janssens John Kalapurakal 《Pediatric blood & cancer》2023,70(Z2):e30090
Radiotherapy (RT) is essential for multimodality treatment of pediatric renal tumors, particularly in higher-risk and metastatic disease. Despite decades of use, particularly for Wilms tumor, there remain controversies regarding RT indications, timing, dose, and targets. To align global management, we address these issues in this international HARMONIsation and CollAboration (HARMONICA) project. There are multiple knowledge gaps and opportunities for future research including: (1) utilization of advanced RT technologies, including intensity-modulated RT, proton beam therapy, combined with image-guided RT to reduce target volumes; (2) impact of molecular biomarkers including loss of heterozygosity at 1p, 16q, and 1q gain on RT indications; (3) mitigation of reproductive toxicity following RT; (4) promotion of RT late effects research; and (5) support to overcome challenges in RT utilization in low- and middle-income countries where 90% of the world's children reside. Here, we outline current status and future directions for RT in pediatric renal tumors. 相似文献
2.
3.
4.
5.
Amy B. Hont Benoit Dumont Kathryn S. Sutton John Anderson Alex Kentsis Jarno Drost Andrew L. Hong Arnauld Verschuur 《Pediatric blood & cancer》2023,70(Z2):e30110
This review highlights the role of several immunomodulating elements contributing to the tumor microenvironment of various pediatric renal tumors including Wilms tumor. The roles of innate and adaptive immune cells in renal tumors are summarized as well as immunomodulatory cytokines and other proteins. The expression and the predictive role of checkpoint modulators like PD-L1 and immunomodulating proteins like glypican-3, B7-H3, COX-2 are highlighted with a translational view toward potential therapeutic innovations. We further discuss the current state of preclinical models in advancing this field of study. Finally, examples of clinical trials of immunomodulating strategies such as monoclonal antibodies and chimeric antigen receptor T (CAR-T) cells for relapsed/refractory/progressive pediatric renal tumors are described. 相似文献
6.
Outcome of renal tumors registered in Japan Wilms Tumor Study‐2 (JWiTS‐2): A report from the Japan Children's Cancer Group (JCCG) 下载免费PDF全文
Tsugumichi Koshinaga Tetsuya Takimoto Takaharu Oue Hajime Okita Yukichi Tanaka Miwako Nozaki Kunihiko Tsuchiya Eisuke Inoue Masayuki Haruta Yasuhiko Kaneko Masahiro Fukuzawa 《Pediatric blood & cancer》2018,65(7)
7.
Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature—A report from the SIOP Renal Tumor Study Group 下载免费PDF全文
Janna A. Hol Marry M. van den Heuvel‐Eibrink Norbert Graf Kathy Pritchard‐Jones Jesper Brok Harm van Tinteren Lisa Howell Arnauld Verschuur Christophe Bergeron Leo Kager Serena Catania Annelies M. C. Mavinkurve‐Groothuis 《Pediatric blood & cancer》2018,65(2)
While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan‐containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate‐risk (CR and PR) and blastemal‐type histologies (PR). Two patients were alive at last follow‐up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT. 相似文献
8.
Samuel D. Abbou David S. Shulman Steven G. DuBois Brian D. Crompton 《Pediatric blood & cancer》2019,66(5)
Circulating tumor DNA can be detected in the blood and body fluids of patients using ultrasensitive technologies, which have the potential to improve cancer diagnosis, risk stratification, noninvasive tumor profiling, and tracking of treatment response and disease recurrence. As we begin to apply “liquid biopsy” strategies in children with cancer, it is important to tailor our efforts to the unique genomic features of these tumors and address the technical and logistical challenges of integrating biomarker testing. This article reviews the literature demonstrating the feasibility of applying liquid biopsy to pediatric solid malignancies and suggests new directions for future studies. 相似文献
9.
10.
11.
12.
13.
Antoine Lin Hlne Sudour‐Bonnange Virginie Languillat‐Fouquet Herv Brisse Sabine Irtan Arnauld Verschuur Sabine Sarnacki Estelle Thbaud Aurore Coulomb‐L'Hermine Anne Notz‐Carrre Jean Michon Marie‐Dominique Tabone Ccile Boulanger Isabelle Pellier Claire Freycon Georges Audry Frdrique Dijoud Magali Morelle Christophe Bergeron Claudia Pasqualini 《Pediatric blood & cancer》2020,67(6)
14.
Gregory A. Norris Jacquelyn Garcia Todd C. Hankinson Michael Handler Nicholas Foreman David Mirsky Nicholas Stence Kathleen Dorris Adam L. Green 《Pediatric blood & cancer》2019,66(6)
Preoperative diagnosis for tumors arising in the optic chiasm/sellar/suprasellar region in children is helpful to determine surgical necessity and approach, given the high operative risk in this area. We evaluated the ability to differentiate tumor type by preoperative neuroimaging. Thirty‐eight of 53 tumors were correctly diagnosed by neuroimaging based on final pathologic diagnosis (prediction accuracy 72%). Prediction accuracies were 87% (20/23) for craniopharyngioma, 79% (11/14) for optic pathway glioma, 64% (7/11) for germ cell tumor, and 0% (0/5) for Langerhans cell histiocytosis. Diagnosis of optic chiasm/sellar/suprasellar tumors in children by imaging alone should be considered when biopsy is considered high risk. 相似文献
15.
Maddy Artunduaga Meryle Eklund Justine N. van der Beek Matthew Hammer Annemieke S. Littooij Jesse K. Sandberg Jens-Peter Schenk Sabah Servaes Sudha Singh Ethan A. Smith Abhay Srinavasan Geetika Khanna 《Pediatric blood & cancer》2023,70(Z4):e30004
Malignant renal tumors account for approximately 6% of pediatric malignancies, with Wilms tumor (WT) representing approximately 90% of pediatric renal tumors. This paper provides consensus-based imaging guidelines for the initial evaluation of a child with suspected WT and follow-up during and after therapy co-developed by the Children's Oncology Group (COG) Diagnostic Imaging and Society for Pediatric Radiology (SPR) oncology committees. The guidelines for Wilms Tumor Imaging in the Society of International Pediatric Oncology (SIOP) are briefly discussed to highlight some of the differences in imaging approach. 相似文献
16.
Jaime Libes Janna Hol Joaquim Caetano de Aguirre Neto Kelly L. Vallance Harm van Tinteren Daniel J. Benedetti Gema Lucia Ramirez Villar Catriona Duncan Peter F. Ehrlich 《Pediatric blood & cancer》2023,70(1):e30006
Pediatric renal tumors account for 3%–11% of childhood cancers, the most common of which is Wilms tumor or nephroblastoma. Epidemiology plays a key role in cancer prevention and control by describing the distribution of cancer and discovering risk factors for cancer. Large pediatric research consortium trials have led to a clearer understanding of pediatric renal tumors, identification of risk factors, and development of more risk-adapted therapies. These therapies have improved event-free and overall survival for children. However, several challenges remain and not all children have benefited from the improved outcomes. In this article, we review the global epidemiology of pediatric renal tumors, including key consortium and global studies. We identify current knowledge gaps and challenges facing both high and low middle-incomes countries. 相似文献
17.
Richard E. Overman Tanvi T. Kartal Aaron J. Cunningham Elizabeth A. Fialkowski Bindi J. Naik‐Mathuria Sanjeev A. Vasudevan Marcus M. Malek Ranjeet Kalsi Hau D. Le Linda Cherney Stafford Timothy B. Lautz Benjamin T. Many Rachel E. Jones Andreana Bütter Jacob Davidson Andrew Williams Roshni Dasgupta Jana Lewis Misty Troutt Jennifer H. Aldrink Sara A. Mansfield Dave R. Lal Jerry Xiao Rebecka L. Meyers Scott S. Short Erika A. Newman 《Pediatric blood & cancer》2020,67(5)
18.
Kasap B 《Pediatric transplantation》2011,15(7):673-685
SRL, an mTOR inhibitor that inhibits cell cycle progression, represents an important alternative to CNIs, which are still the cornerstones of pediatric solid organ tx. Because there are still limited data on SRL use among pediatric solid organ recipients, further studies are needed to verify the efficacy and safety of SRL. It has unique pharmacokinetic characteristics concerning dosing intervals and reduction of the dose in combination with other immunosuppressants. SRL also has antineoplastic, antiviral, and antiatherogenic advantages over other immunosuppressive agents. The adverse effects of SRL including thrombocytopenia, hyperlipidemia, proteinuria, impaired wound healing, mouth ulcers, edema, male hypogonadism, TMA, and interstitial pneumonitis must be considered carefully in pediatric population. This article reviews the most recent data on SRL application in the field of pediatric renal tx. 相似文献
19.
20.
Reliability of intraoperative frozen section for the diagnosis of renal tumors suspicious for malignancy in children and adolescents 下载免费PDF全文
Alonso Carrasco Jr. Brian T. Caldwell Carrye R. Cost Brian S. Greffe Timothy P. Garrington Jennifer L. Bruny Jennifer O. Black Nicholas G. Cost 《Pediatric blood & cancer》2017,64(8)